Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors?
We read with great interest the invited review by Fojecki and colleagues regarding the role of extracorporeal shock wave therapy (ESWT) in urology . The authors systematically reviewed randomized controlled trials (RCTs) published before November 9, 2015, to have examined ESWT in urologic diseases, including Peyronie’s disease, chronic pelvic pain and erectile dysfunction (ED). In the article, they focused on the role of ESWT in patients with ED who had previously responded to a phosphodiesterase type 5 inhibitor (PDE5i). Those with ED unresponsive to PDE5is were not mentioned, likely due to lack of RCTs and the assumption that they probably also benefit from ESWT treatment.
The first double-blind, sham-controlled study examining the role of ESWT for PDE5i non-responders was published at the end of 2015  and reported that penile ESWT can convert a PDE5i non-responder to a responder. In terms of erection hardness score (EHS) and the erectile function (EF) domain of...
KeywordsErectile Dysfunction Erectile Function Chronic Pelvic Pain Extracorporeal Shock Wave Therapy Phosphodiesterase Type
This work was supported by the Science and Technology Foundation of the Sichuan Province (2014JY0183 to Yi-ping Lu) and the Science and Technology Foundation of the Chengdu City (2014-HM01-00301-SF to Yi-ping Lu).
ZJ Zou and YP Lu wrote and edited the manuscript. ZH Liu and LY Tang collected the data.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Chung E, Cartmill R (2015) Evaluation of clinical efficacy, safety and patient satisfaction rate after low-intensity extracorporeal shockwave therapy for the treatment of male erectile dysfunction: an Australian first open-label single-arm prospective clinical trial. BJU Int 115(suppl 5):46–49CrossRefPubMedGoogle Scholar